New Publication: Sana’s Gene-Edited Islets Continue to Make Insulin
What’s Happening? A new publication in The New England Journal of Medicine provides more detail about the first person with type 1 diabetes (T1D) treated with Sana Biotechnology’s gene-edited islets. This person is still making insulin 14+ months after their islet transplant—without immunosuppressants! What to Know About Sana’s Gene-Edited Islets Sana’s novel cell therapy approach […]
From T1D Toddler to Resilient Adult: Jessie Stover Shares her Story
Spotlight on Jessie Stover Jessie Stover is the Development Manager at Breakthrough T1D’s Indiana Chapter. Stover was born and raised in Evansville, Indiana, and she now lives in Indianapolis with her two cats, Milo and Zuko. She enjoys reading, crafting, concerts, and “baking gluten-free desserts so good that no one can tell they’re gluten-free.” Here, […]
A Roadmap to Accelerate Cell Therapies into Clinical Trials
What’s Happening? A new Breakthrough T1D publication lays out the first clear preclinical testing and manufacturing roadmap for getting islet cell therapies for type 1 diabetes (T1D) into human clinical trials faster. What is This Publication About? Before any new therapy—including islet cell therapies for T1D—can move into in-human clinical trials, they need to go […]
What is Time in Range?
Time in range is a metric measured by continuous glucose monitors. Learn about why it matters and future applications.
Golf Champion J.J. Spaun: A Hero Who’s One of Us
Golf champion J.J. Spaun discusses his game and life with T1D with dedicated Breakthrough T1D supporter Moira McCarthy.
Could Drugs Like Ozempic also Benefit People with Type 1 Diabetes?
Learn more about GLP-1 therapies and SGLT inhibitors, and how drugs like Ozempic may one day be able to help people with type 1 diabetes.
Tzield Approved for Stage 3 T1D in the U.S.
What’s Happening? In an exciting update for the type 1 diabetes (T1D) community, Tzield—the first disease-modifying therapy approved by the FDA to delay progression of stage 2 T1D—has now been approved by the FDA for use in stage 3 T1D. People aged 8-17 with stage 3 T1D will soon be able to get Tzield in clinics (with a prescription) if […]
Everything you need to know about ADA 2026
Breakthrough T1D was on site in New Orleans, LA from June 5-8 for the American Diabetes Association’s (ADA) 86th Scientific Sessions. Check out all of our coverage below, including type 1 diabetes (T1D) advances across all our mission priority areas and several Breakthrough T1D-funded researchers and staff driving progress forward. In case you missed it, […]
Cell Therapy Clinical Trials: Breaking Down the Science
Breakthrough T1D is here to answer all of your questions about islet cell therapies, from the research lab to real-world treatments.
ADA 2026 Recap: Days 3 and 4
ADA’s 86th Scientific Sessions This event is one of the largest diabetes conferences in the world, bringing together over 11,000 attendees to share and learn about cutting-edge research and advancements toward cures. Each year, Breakthrough T1D-funded researchers highlight their work, demonstrating the progress we’re making toward achieving our mission. Leading experts will present over 100 […]
